Skip to main content

Table 3 Summary of the meta-analyses done to assess therapeutic efficacy of umbilical cord-derived stem cell transplantation in subjects who received intervention compared to control subjects who did not receive that intervention

From: Therapeutic efficacy of umbilical cord-derived stem cells for diabetes mellitus: a meta-analysis study

Study name and year Number of subjects SC group Number of subjects Control group Study weight SMD Lower CI Upper CI Type of DM Type of UC-SC
Mean SD Mean SD
HbA1c%
 Hu et al., 2013 15 6.100 1.100 14 7.400 1.900 18.7 − 0.821 − 1.580 − 0.063 T1DM WJ-MSCs
 Hu et al., 2016 31 6.000 0.700 30 7.100 0.800 22.5 − 1.446 − 2.010 − 0.883 T2DM WJ-MSCs
 Cai et al., 2016 21 7.500 1.000 21 8.800 0.900 20.4 − 1.341 − 2.010 − 0.671 T1DM WJ-MSCs
 Chen et al., 2016 6 6.820 0.530 6 7.820 0.310 9.6 − 2.125 − 3.541 − 0.710 T2DM WJ-MSCs
 Haller et al., 2013 10 7.100 1.290 5 7.400 0.400 13.5 − 0.258 − 1.335 0.820 T1DM UCB
 Giannopoulou et al., 2013 7 7.250 0.440 10 7.225 1.070 15.2 0.027 − 0.939 0.993 T1DM UCB
C-peptide levels (ng/ml)
 Hu et al., 2013 a 15 1.350 0.230 14 0.810 0.300 16.9 1.973 1.085 2.861 T1DM WJ-MSCs
 Hu et al., 2016 a 31 2.660 0.330 30 1.670 0.250 17.3 3.331 2.555 4.106 T2DM WJ-MSCs
 Cai et al., 2016 a 21 0.060 0.030 21 0.030 0.020 17.7 1.154 0.501 1.808 T1DM WJ-MSCs
 Chen et al., 2016 c 6 0.700 0.380 6 0.220 0.130 15.4 1.560 0.267 2.852 T2DM WJ-MSCs
 Haller et al., 2013 b, * 10 0.163 0.181 5 0.207 0.211 16.2 − 0.217 − 1.293 0.859 T1DM UCB
 Giannopoulou et al., 2013 b 7 0.390 0.388 10 1.032 0.800 16.5 − 0.914 − 1.928 0.099 T1DM UCB
  1. aFasting C-peptide
  2. bStimulated peak C-peptide
  3. cStimulated early phase C-peptide secretion function ΔCP30/ΔG30
  4. *Measuring unit; pmol/L